Global Peer Reviewed Studies

Pancreatitis remains one of the most challenging conditions in small animal practice, painful, often recurrent, and potentially fatal. This 2025 clinical study explored a novel approach using a membrane-free stem cell extract (MF-STEM), a third-generation stem cell therapy derived from human adipose tissue and free of membrane components, reducing immunogenicity and simplifying administration.

This 2021 systematic review brings together six clinical studies on the use of adipose-derived mesenchymal stem cells (AD-MSCs) injected directly into the hip joint of dogs with osteoarthritis.

This was a randomised, double-blinded, placebo-controlled, multicentre trial involving 21 client-owned dogs with mild to moderate bilateral hip OA of at least six months' duration.

As the evidence base for regenerative therapies grows, studies directly comparing treatment modalities are particularly valuable. One such study, published in 2014, aimed to assess the clinical efficacy of autologous adipose-derived mesenchymal stem cells (AD-MSCs) versus plasma rich in growth factors (PRGF) in client-owned dogs with hip osteoarthritis.

This 2019 study by Taguchi et al. explored a specific and clinically relevant question: Does donor age affect the immunomodulatory function of adipose-derived mesenchymal stem cells (AD-MSCs) in dogs? The short answer is yes, and the implications are important for how and when we consider stem cell collection and use.

This study compared five MSC types and found that adipose-derived cells had the shortest doubling time, and the most rapid adipogenic and osteogenic differentiation. That makes adipose not only accessible, but biologically efficient.

This study evaluates both the production of canine adipose-derived MSCs and their potential for therapeutic use in dogs with chronic elbow osteoarthritis.

This study adds to a growing body of in vitro evidence showing that autologous adipose-derived MSCs (AD-MSCs) may offer safer and more consistent immunomodulatory effects than allogeneic cells.

This paper presents the first documented case of successful long-term treatment of spontaneously occurring DLSS using autologous AD-MSCs, with a sustained clinical response lasting over 4.5 years.

This research highlights the significant clinical improvements observed after a single injection of these cells, underscoring their potential as a safe and effective therapy for this common degenerative joint disease.

This review highlights the remarkable immunomodulatory capabilities of MSCs and their potential to offer safer and more effective alternatives to traditional long-term pharmacotherapy.

At Elita, this kind of work reinforces one of our core beliefs, that early collection matters. The decision to bank stem cells during routine procedures (like desexing) isn't just convenient, it may actually improve the therapeutic quality of the treatment derived from stored cells.